Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Depreciation & Amortization (CF): 2011-2024

Historic Depreciation & Amortization (CF) for Abeona Therapeutics (ABEO) over the last 14 years, with Dec 2024 value amounting to $2.0 million.

  • Abeona Therapeutics' Depreciation & Amortization (CF) rose 24.85% to $608,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 13.75%. This contributed to the annual value of $2.0 million for FY2024, which is 12.41% down from last year.
  • Per Abeona Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2.0 million for FY2024, which was down 12.41% from $2.3 million recorded in FY2023.
  • Abeona Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $4.6 million during FY2020, with a 5-year trough of $2.0 million in FY2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $2.3 million (2023), whereas its average is $2.5 million.
  • Data for Abeona Therapeutics' Depreciation & Amortization (CF) shows a maximum YoY tumbled of 41.35% (in 2020) over the last 5 years.
  • Over the past 5 years, Abeona Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $4.6 million in 2020, then dropped by 29.13% to $3.2 million in 2021, then decreased by 4.83% to $3.1 million in 2022, then declined by 26.03% to $2.3 million in 2023, then declined by 12.41% to $2.0 million in 2024.